Economic Burden of Acute Myeloid Leukemia in European Union: Results from a Systematic Review of Literature [0.03%]
欧洲急性髓系白血病的经济负担：系统文献回顾的结果
Alisha Saeed,Zermina Tasleem,Sohail Ayaz Muhammad et al.
Alisha Saeed et al.
Background: Acute myeloid leukemia (AML) is a heterogenous malignancy whose management is associated with considerable healthcare resource utilization and high expenditures because of recurrent and extended hospitalizatio...
Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults [0.03%]
Daridorexant对成人慢性失眠障碍的药物治疗的成本效益分析
Andrew H Briggs,François-Xavier Chalet,Jacie Cooper et al.
Andrew H Briggs et al.
Objective: Daridorexant 50 mg is recommended for treating chronic insomnia in England, Wales (NICE, 2023) and Scotland (Scottish Medicines Consortium, 2024). This study examines the model and cost-effectiveness profile th...
Cost-Benefit Analysis of the Enhancing Men's Awareness of Testicular diseases (E-MAT) Feasibility Trial: A Virtual Reality Experience to Increase Testicular Knowledge and Self-Examination among Male Athletes [0.03%]
提高男性对睾丸疾病的认知(E-MAT)可行性试验的成本效益分析：一项增强男性运动员睾丸知识和自我检查的虚拟现实体验
Aileen Murphy,Ann Kirby,Federica De Blasio et al.
Aileen Murphy et al.
Background: Virtual reality (VR) is potentially effective in raising awareness of testicular diseases, promoting self-examination and early help-seeking among men. This paper presents an early economic evaluation explorin...
Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database [0.03%]
呼吸道合胞病毒及成人急性呼吸道感染的成本和并发症：来自德国保险数据库的分析
Pavo Marijic,Roman Kliemt,Martin Krammer et al.
Pavo Marijic et al.
Background: Respiratory syncytial virus (RSV) infections pose health and economic burdens to adults. Using claims data, we estimated RSV-associated costs, healthcare resource utilization (HCRU), and complication rates fro...
Healthcare Expenditure Trajectories in the Last 5 Years of Life: A Retrospective Cohort Study of Decedents with Advanced Cancer and End-Stage Organ Diseases [0.03%]
生命最后五年医疗费用趋势分析：晚期癌症与终末期器官疾病逝者群体的回溯性研究
Sheryl Hui-Xian Ng,Palvinder Kaur,Laurence Lean Chin Tan et al.
Sheryl Hui-Xian Ng et al.
Background: Patients with nonmalignant end-stage organ diseases often incur healthcare costs in the last year of life that are disproportionately higher than in the period prior. Studies on healthcare expenditure (HCE) tr...
Effects of Generic Entry on Market Shares and Prices of Originator Drugs: Evidence from Chinese Pharmaceutical Market [0.03%]
专利药品市场中的市场份额和价格对通用药物进入的反应——来自中国医药市场的证据
Weimiao Li,Xiaoyu Li,Yaoguang He et al.
Weimiao Li et al.
Objectives: This article analyzes how market shares and prices for brand-name drugs are affected by generic competition in China. Methods: ...
Predicting Danish EQ-5D-5L Utilities Based on United Kingdom EQ-5D-3L Utilities for Use in Health Economic Models [0.03%]
基于英国EQ-5D-3L效用值预测丹麦EQ-5D-5L效用值用于卫生经济学模型中的应用
Einar B Torkilseng,Nathan Clarke,Liza Sopina et al.
Einar B Torkilseng et al.
Objectives: Since 2021, the Danish Medicines Council recommends the use of the Danish EQ-5D-5L value set when estimating utilities. The aim of this research was to develop and validate an algorithm that can accurately pre...
Cost Effectiveness of Left Ventricular Assist Devices (LVADs) as Destination Therapy: A Systematic Review [0.03%]
左心室辅助装置（LVAD）作为终点治疗的成本效益：系统性评价
Tuba Saygın Avşar,Louise Jackson,Pelham Barton et al.
Tuba Saygın Avşar et al.
Objectives: Left ventricular assist devices (LVADs) can extend life and improve quality of life among advanced heart failure patients ineligible for transplantation (destination therapy). High-quality evidence on the cost...
Do We Understand Unmet Need? A Proposal to Use Length-Of-Life Equivalent (LOLE) as a Patient-Centric Measure of Unmet Need [0.03%]
我们理解未满足的需求吗？提出使用寿命当量（LOLE）作为以患者为中心的未满足需求测量方法
Kevin Marsh,Robert F Reynolds,Linda Nelsen et al.
Kevin Marsh et al.
Many decision-makers have emphasized the importance of leveraging patient experience data to measure unmet need. However, there is no standardized, patient-centric unmet need measure that formalizes how the value judgements inherent in such...
Publisher Correction: Pricing for Multi-Indication Drugs in the Italian Regulatory Context [0.03%]
出版更正：意大利监管环境中的多适应症药物定价问题
Maria Grazia Ursino,Annalisa Milano,Filippo Viti De Angelis et al.
Maria Grazia Ursino et al.
Published Erratum
PharmacoEconomics - open. 2025 Feb 14. DOI:10.1007/s41669-025-00566-2 2025